Baird Medical to Showcase Microwave Ablation Technology at Major Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2024
0mins
Should l Buy BDMD?
Source: PRnewswire
Baird Medical Investment Holdings Ltd's stock fell 5.16% as it crossed below the 5-day SMA amid broader market gains, with the Nasdaq-100 up 1.08% and the S&P 500 up 0.65%.
The company is set to participate in three major clinical conferences this quarter, including the North American Society for Interventional Endocrinology and the International Society of Innovative Technologies for Endocrine Surgery. At these events, Baird Medical will demonstrate its proprietary microwave ablation technology, which treats benign thyroid nodules without traditional surgery, aiming to enhance market penetration and drive sales growth through increased physician awareness.
Baird Medical's leadership in the thyroid microwave ablation market, particularly in China, and its plans for strategic collaborations with academic institutions indicate a strong potential for growth in both domestic and international markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDMD
About BDMD
Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baird Medical Reports FY 2025 Financial Results
- Financial Decline: Baird Medical reported a GAAP EPS of -$0.98 for FY 2025 with revenue of $22.5 million, a significant drop from $32.7 million in 2024, indicating major challenges in revenue generation and profitability.
- Gross Margin Erosion: The gross profit for 2025 was $18.9 million, with a gross margin of 83.8%, down from 88.2% in 2024, reflecting increased pressure on cost control and market competitiveness.
- Surge in Operating Expenses: Total operating expenses soared to $44.5 million in 2025 from $17.3 million in 2024, driven by higher selling, general and administrative, and R&D expenses, highlighting the company's ongoing investment in commercial expansion and product innovation.
- Increased R&D Investment: R&D expenses rose significantly from $6.2 million in 2024 to $20.1 million in 2025, demonstrating the company's commitment to technological innovation and product development, despite the short-term financial strain.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven challenges in Mainland China that led to reduced sales volume and pricing pressure, highlighting significant market difficulties.
- Executive Appointment: The company appointed Mark Saxton as CEO of Baird U.S. to spearhead commercial expansion in the U.S. market; with 25 years of experience in medical technology, Saxton is expected to drive new growth opportunities for the company.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025 from $6.2 million in 2024, indicating the company's commitment to product innovation and market expansion, aimed at enhancing the competitiveness of its Microwave Ablation technology.
- Widening Operating Loss: The operating loss for 2025 reached $25.6 million, significantly up from $15.3 million in 2024, reflecting the high operational costs and market pressures faced during the company's expansion efforts.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven market dynamics in Mainland China, necessitating an accelerated geographic expansion strategy to mitigate market challenges.
- Executive Appointment: The appointment of Mark Saxton as CEO of Baird U.S. is expected to enhance commercial activities in the U.S. market, leveraging his 25 years of experience to drive market penetration and technology promotion in this critical region.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025, a 225% increase from 2024, aimed at advancing microwave ablation technology and expanding market reach, underscoring the company's commitment to future growth.
- Widening Operating Loss: The company reported an operating loss of $25.6 million in 2025, significantly higher than the $15.3 million loss in 2024, reflecting the dual pressures of rising operational costs and declining revenues, necessitating strategic measures to improve financial health.
See More
Baird Medical Successfully Hosts Clinical Training in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
- Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
- Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
- Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.
See More
Baird Medical Successfully Conducts Clinical Training Workshops in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia at EKA Medika Hospital and RSCM Hospital, providing local physicians with hands-on experience in Microwave Ablation technology, thereby enhancing the company's influence in the Southeast Asian market.
- Strategic Expansion: The workshops not only equipped regional healthcare providers with advanced tools and practical knowledge but also facilitated Baird Medical's strategic expansion in Southeast Asia, which is expected to improve patient care quality and drive business growth.
- Market Leadership: As a market leader in minimally invasive diagnostics and treatment, Baird Medical's solutions are utilized in over 30 prestigious hospitals in the U.S., further solidifying its competitive advantage in the global medical device market.
- Future Development Vision: Baird Medical is committed to fostering strategic collaborations with leading academic institutions to advance the research and development of surgical robotic systems and innovative minimally invasive surgical instruments, aiming to enhance patient outcomes through precision technology and demonstrate its foresight in medical innovation.
See More
Baird Medical Secures Regulatory Approval in Argentina
- International Expansion Milestone: Baird Medical's regulatory clearance in Argentina marks a strategic advancement in its mission to promote Microwave Ablation technology globally, which is expected to significantly enhance the company's competitiveness in international markets.
- Enhanced Certification Portfolio: The approval in Argentina enriches Baird Medical's international certification portfolio, which already includes the U.S. FDA, Indonesia, Malaysia, and Vietnam, thereby strengthening its foundation for global business expansion.
- Regulatory Pipeline Advancement: The company is actively seeking formal registrations in key markets such as Egypt, Sri Lanka, the Philippines, and Pakistan, demonstrating its commitment to meeting the rising global healthcare demand.
- Market Leadership Position: Baird Medical holds a leading position in the thyroid microwave ablation device market in China, and with its products gradually expanding into over 20 countries, it is poised to further solidify its leadership in the global medical device industry.
See More
Baird Medical Reports FY 2025 Financial Results
- Financial Decline: Baird Medical reported a GAAP EPS of -$0.98 for FY 2025 with revenue of $22.5 million, a significant drop from $32.7 million in 2024, indicating major challenges in revenue generation and profitability.
- Gross Margin Erosion: The gross profit for 2025 was $18.9 million, with a gross margin of 83.8%, down from 88.2% in 2024, reflecting increased pressure on cost control and market competitiveness.
- Surge in Operating Expenses: Total operating expenses soared to $44.5 million in 2025 from $17.3 million in 2024, driven by higher selling, general and administrative, and R&D expenses, highlighting the company's ongoing investment in commercial expansion and product innovation.
- Increased R&D Investment: R&D expenses rose significantly from $6.2 million in 2024 to $20.1 million in 2025, demonstrating the company's commitment to technological innovation and product development, despite the short-term financial strain.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven challenges in Mainland China that led to reduced sales volume and pricing pressure, highlighting significant market difficulties.
- Executive Appointment: The company appointed Mark Saxton as CEO of Baird U.S. to spearhead commercial expansion in the U.S. market; with 25 years of experience in medical technology, Saxton is expected to drive new growth opportunities for the company.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025 from $6.2 million in 2024, indicating the company's commitment to product innovation and market expansion, aimed at enhancing the competitiveness of its Microwave Ablation technology.
- Widening Operating Loss: The operating loss for 2025 reached $25.6 million, significantly up from $15.3 million in 2024, reflecting the high operational costs and market pressures faced during the company's expansion efforts.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven market dynamics in Mainland China, necessitating an accelerated geographic expansion strategy to mitigate market challenges.
- Executive Appointment: The appointment of Mark Saxton as CEO of Baird U.S. is expected to enhance commercial activities in the U.S. market, leveraging his 25 years of experience to drive market penetration and technology promotion in this critical region.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025, a 225% increase from 2024, aimed at advancing microwave ablation technology and expanding market reach, underscoring the company's commitment to future growth.
- Widening Operating Loss: The company reported an operating loss of $25.6 million in 2025, significantly higher than the $15.3 million loss in 2024, reflecting the dual pressures of rising operational costs and declining revenues, necessitating strategic measures to improve financial health.
See More
Baird Medical Successfully Hosts Clinical Training in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
- Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
- Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
- Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.
See More
Baird Medical Successfully Conducts Clinical Training Workshops in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia at EKA Medika Hospital and RSCM Hospital, providing local physicians with hands-on experience in Microwave Ablation technology, thereby enhancing the company's influence in the Southeast Asian market.
- Strategic Expansion: The workshops not only equipped regional healthcare providers with advanced tools and practical knowledge but also facilitated Baird Medical's strategic expansion in Southeast Asia, which is expected to improve patient care quality and drive business growth.
- Market Leadership: As a market leader in minimally invasive diagnostics and treatment, Baird Medical's solutions are utilized in over 30 prestigious hospitals in the U.S., further solidifying its competitive advantage in the global medical device market.
- Future Development Vision: Baird Medical is committed to fostering strategic collaborations with leading academic institutions to advance the research and development of surgical robotic systems and innovative minimally invasive surgical instruments, aiming to enhance patient outcomes through precision technology and demonstrate its foresight in medical innovation.
See More
Baird Medical Secures Regulatory Approval in Argentina
- International Expansion Milestone: Baird Medical's regulatory clearance in Argentina marks a strategic advancement in its mission to promote Microwave Ablation technology globally, which is expected to significantly enhance the company's competitiveness in international markets.
- Enhanced Certification Portfolio: The approval in Argentina enriches Baird Medical's international certification portfolio, which already includes the U.S. FDA, Indonesia, Malaysia, and Vietnam, thereby strengthening its foundation for global business expansion.
- Regulatory Pipeline Advancement: The company is actively seeking formal registrations in key markets such as Egypt, Sri Lanka, the Philippines, and Pakistan, demonstrating its commitment to meeting the rising global healthcare demand.
- Market Leadership Position: Baird Medical holds a leading position in the thyroid microwave ablation device market in China, and with its products gradually expanding into over 20 countries, it is poised to further solidify its leadership in the global medical device industry.
See More
